In Japan, no pulsatile ventricular assist devices are available specifically for use in children. Pumps designed for adults are thus often used in children. We report herein a case of end-stage heart failure in a 3-year old girl (height 100.4 cm; body weight 16.2 kg; body surface area 0.66 m2) who underwent implantation with an adult-sized Toyobo-NCVC left ventricular assist device (Toyobo-National Cardiovascular Center, Osaka, Japan) in our unit. We started with the driving mode to "full-fill, full-empty" mode. The problem was difficult-to-treat hypertension due to excessive stroke volume induced by the left ventricular assist device. Aggressive administration of antihypertensive therapy was needed. Successful heart transplantation was performed in Germany 5 months after beginning support with the Toyobo-NCVC left ventricular assist device.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11748-008-0252-9 | DOI Listing |
ASAIO J
January 2025
Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
The use of an alteplase (Activase) purge solution to address Impella ventricular assist device "thrombosis" or "purge system occlusion" has been mainly documented with earlier generation Impella devices (CP, 2.5, 5.0).
View Article and Find Full Text PDFJ Cardiovasc Electrophysiol
January 2025
TriHealth Heart & Vascular Institute, Cincinnati, Ohio, USA.
Introduction: A leadless pacemaker (LLPM) was recommended for a patient with intermittent complete heart block and near-syncope.
Methods And Results: Delivery of LLPM is through a large sheath that has limited deflection and steerability. This report describes the successful deployment of a ventricular LLPM in a patient with prior surgical correction of AV septal defect with subsequent significant right atrial enlargement.
Ann Card Anaesth
January 2025
Department of Cardiothoracic Anesthesiology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
This narrative review discusses the various challenges associated with the presence of a left ventricular assist device (LVAD) during pregnancy. Given the hemodynamic and coagulation changes associated with pregnancy, the presence of an LVAD adds a layer of complexity with respect to optimal management. This review will discuss the anesthetic considerations when dealing with this subset of patients who may have other comorbidities alongside their advanced heart failure.
View Article and Find Full Text PDFJ Crit Care
January 2025
Hospital Saint-Louis et Université Paris Cité, Assistance Publique-Hôpitaux de Paris, France. Electronic address:
Purpose: Onco-hematological (OH) patients face significant cardiovascular risks due to malignancy and drug toxicity. Data are limited on the characteristics and outcomes of OH patients with cardiogenic shock (CS) in intensive care units (ICUs).
Methods: This multicenter retrospective study included 214 OH patients with CS across 22 ICUs (2010-2021).
Surg Pract Sci
June 2024
Baylor Scott and White, The Heart Hospital, 4708 Alliance Blvd, Suite 540, Plano, TX, United States.
Introduction: Although left ventricular assist device (LVAD) implantation is associated with improved survival in patients with end-stage heart failure, the impact of preoperative pulmonary function on short-term outcomes is unclear.
Methods: We conducted a retrospective review of all primary LVAD implants at a single institution. Common measures of preoperative pulmonary function were evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!